

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

205552Orig2s000

CROSS DISCIPLINE TEAM LEADER REVIEW

Cross-Discipline Team Leader Review

Date	See stamp date
From	R. Angelo de Claro, M.D.
Subject	Cross-Discipline Team Leader Review
NDA/BLA #	NDA 205552 (Original-2)
Applicant	Pharmacyclics, Inc.
Date of Submission	28 June 2013
PDUFA Goal Date	28 February 2014
Proprietary Name / Established (USAN) names	Imbruvica
Dosage forms / Strength	Capsules, 140 mg
Proposed Indication(s)	Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy
Recommended:	Approval

Material Reviewed/Consulted	Reviewer
Clinical Review	Nicole Verdun, M.D. / R. Angelo de Claro, M.D.
Statistical Review	Yun Wang, Ph.D. / Lei Nie, Ph.D.
Pharmacology Toxicology Review	Shwu-Luan Lee, Ph.D., Haw-Jyh (Brian) Chiu, Ph.D., George Ching-Jey Chang, Ph.D., Margaret E. Brower, Ph.D. / Haleh Saber, Ph.D. / John Leighton, Ph.D.
ONDQA-CMC and Biopharmaceutic Reviews	CMC: Donghao (Robert) Lu, Ph.D. (Drug substance)/ Xiao-Hong Chen, Ph.D. (Drug product)/ Biopharm: John Duan, Ph.D. /Angelica Dorantes, Ph.D. Microbiology: Bryan Riley, Ph.D. ONDQA: Ramesh Sood, Ph.D. (Tertiary Review)
Clinical Pharmacology Review	Elimika Pfuma, PharmD, Ph.D., Julie Bullock, PharmD, Rosane Charlab Orbach, PhD, Bahru Habtemariam, PharmD, Yuzhuo Pan, PhD, Anshu Marathe, PhD, Ping Zhao PhD
OSI/DGCPC	Anthony Orencia, M.D. / Janice Pohlman, M.D., M.P.H.
OSE/DRISK	Joyce Weaver, Pharm.D. / Cynthia LaCivita, Pharm.D.
OSE/DMEPA	Kevin Wright, Pharm.D. / Yelena Maslov, Pharm.D.
OSE/DPV	Katherine Coyle, Pharm.D. / Tracy Salaam, Pharm.D.
Patient Labeling Team (DMPP)	Karen Dowdy, RN, BSN / Barbara Fuller RN, MSN

1. Introduction

On June 28, 2013, Pharmacyclics Inc. (Applicant) submitted NDA 205552 Original-2 proposed for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. The Applicant had submitted a concurrent application (NDA 205552 Original-1) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy also on June 28, 2013, and received accelerated approval for the treatment of patients with MCL who have received at least one prior therapy on November 13, 2013.

Imbruvica (ibrutinib) is a first-in-class Bruton's tyrosine kinase inhibitor, which targets the B-cell antigen receptor (BCR) signaling pathway.

The primary basis for the application is the result from clinical trial PCYC-1102-CA, an open-label, single-arm trial of Imbruvica monotherapy in 48 patients with CLL who have received at least one prior therapy.

2. Background

Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adulthood. The National Cancer Institute estimates that 15,680 men and women (9,720 men and 5,960 women) will be diagnosed with CLL in 2013. CLL is a lymphoproliferative neoplasm characterized by an accumulation of monoclonal mature B-cells (CD5+CD23+) in the blood, bone marrow, and secondary lymphatic organs.

Current treatments for CLL are not curative, and relapse, toxicity, and resistance to therapy provide for an unmet medical need. Among patients who relapse or who are refractory to first line treatment, the choice of subsequent therapy depends on age, duration of response to prior therapy, ability to tolerate treatment, disease related manifestations, and the presence of molecular poor-risk features.

The following treatments are FDA-approved for the treatment of CLL: Chlorambucil (1957), Cyclophosphamide (1959), Fludarabine (1991), Alemtuzumab (2007), Bendamustine (2008), Ofatumumab (2009, accelerated approval), Rituximab (2010), and Obinutuzumab (2013).

3. CMC/Device

CMC sections were addressed in the NDA 205552 (Original-1) review. There are no major labeling changes proposed for the CMC sections with NDA 205552 (Original-2).

4. Nonclinical Pharmacology/Toxicology

Nonclinical Pharmacology and Toxicology sections were addressed in the NDA 205552 (Original-1) review. There are no major labeling changes proposed for the Nonclinical Pharmacology and Toxicology sections with NDA 205552 (Original-2).

5. Clinical Pharmacology/Biopharmaceutics

Clinical Pharmacology reviewed the MCL and CLL indications together in the NDA 205552 (Original-1) review, and issued a brief addendum for NDA 205552 Original-2. There are no major labeling changes proposed for the Clinical Pharmacology sections with NDA 205552 (Original-2).

6. Clinical Microbiology

The application did not include clinical microbiology information. Refer to Section 3 of NDA 205552 (Original-1) review for product quality microbiology information.

7. Clinical/Statistical- Efficacy

I agree with the conclusions of the statistical and clinical reviewers for the efficacy of Imbruvica for patients with CLL who have received at least one prior therapy.

The following summarizes the key milestones in the regulatory history. The Applicant submitted the IND for ibrutinib (PCI-32765) on September 8, 2008. Protocol PCYC-1102-CA (single-arm trial in patients with CLL/SLL) was initiated on March 11, 2010. End of Phase 2 (EOP2) meetings to discuss the CLL clinical development program including registrational approach occurred on December 5, 2011, April 30, 2012, July 26, 2012, and September 26, 2012. Fast Track was granted on October 29, 2012 for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have relapsed or have refractory disease and have previously received at least one prior therapy. On March 18, 2013, Breakthrough Therapy designation was granted by the FDA for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma with deletion of the short arm of chromosome 17 (del 17p). Pre-NDA meeting occurred on April 9, 2013.

Efficacy Summary

The safety and efficacy of Imbruvica in patients with CLL who have received at least one prior therapy were evaluated in an open-label, multi-center trial of 48 previously treated patients. The median age was 67 years (range, 37 to 82 years), 71% were male, and 94% were Caucasian. All patients had a baseline ECOG performance status of 0 or 1. The

median time since diagnosis was 80 months and the median number of prior treatments was 4 (range, 1 to 12 treatments). At baseline, 46% of subjects had at least one tumor ≥ 5 cm.

Imbruvica was administered orally at 420 mg once daily until disease progression or unacceptable toxicity. Overall response (ORR) and duration of response (DOR) were assessed using a modified version of the International Working Group CLL Criteria by an Independent Review Committee. The ORR was 58.3% (95% CI: 43.2%, 72.4%), all partial responses. None of the patients achieved a complete response. The DOR ranged from 5.6 to 24.2+ months. The median DOR was not reached.

Primary Reviewer Conclusions

The statistical reviewer concluded that Imbruvica provided durable treatment effect for patients with relapsed or refractory chronic lymphocytic leukemia in Study PCYC-1102-CA.

CDTL Comment: The statistical review was finalized prior to agreement with the Applicant on the ORR results. The ORR of 58.3% (28/48) is acceptable to both the clinical and statistical teams, and differs from the final ORR (56.3%, 27/48) reported in the statistical review based on clarification provided by the Applicant regarding the response profile of 1 patient.

The clinical reviewer concluded that the Applicant has demonstrated the efficacy of Imbruvica in patients with chronic lymphocytic leukemia who have been previously treated.

CDTL Comment: At the time of application submission, the clinical and statistical teams noted lack of independent review committee (IRC) verification of the efficacy results. During the review cycle, the Applicant submitted the requested IRC assessments for the efficacy endpoints.

8. Safety

I concur with the clinical reviewer's conclusions regarding the safety of Imbruvica for the proposed CLL indication.

Safety Summary

The safety profile of Imbruvica was primarily evaluated in 48 patients with previously treated CLL enrolled in PCYC-1102-CA, a single-arm Phase 2 clinical trial. A summary of the key safety findings based on the data cut-off date of December 26, 2013 is listed below:

- The Imbruvica dose was 420 mg once daily. The median exposure duration was 15.6 months.
- All treated subjects experienced at least 1 treatment-emergent adverse event.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.